ASH 2024: Legend CEO Ying Huang on moving Carvykti into earlier settings, potential future competition, beyond BCMA, and more
He discusses this year's Cartitude 4 approval, plus current studies in 1L multiple myeloma. Also, his take on a potential future competitors' data at ASH, other programs, including autoimmune, and plans for an R&D center in Philadelphia.